Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...

Opens in a new tab or window HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus ...

Inavolisib joins Novartis’s first-in-class phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib on the market, but adds a monomeric degrader mechanism of action that could expand its utility.

IPI-549 is an oral, selective phosphoinositide-3-kinase gamma (PI3K-gamma) inhibitor, and the partners believe the combination will help overcome resistance to PD-1s seen in these patients.

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and ...

Selective PI3K-gamma inhibition represents a unique and potentially transformative approach within immuno-oncology (I/O), and IPI-549 has the potential to be a first-in-class therapy. Preclinical ...